STUDY OF THE EFFECT OF SOFOSBUVIR BASED THERAPY ON ESTIMATED GLOMERULAR FILTRATION RATE IN EGYPTIAN CHRONIC HEPATITIS C PATIENTS
Ibrahim, E., Elbealy, M., Nassar, A., Mostafa, H. (2021). STUDY OF THE EFFECT OF SOFOSBUVIR BASED THERAPY ON ESTIMATED GLOMERULAR FILTRATION RATE IN EGYPTIAN CHRONIC HEPATITIS C PATIENTS. EKB Journal Management System, 42(2), 7-13. doi: 10.21608/jmalexu.2021.244166
Elsaied Ibrahim; Mohamed Ahmed Elbealy; Abeer Abdelhafeez Nassar; Hanan Mostafa Mostafa. "STUDY OF THE EFFECT OF SOFOSBUVIR BASED THERAPY ON ESTIMATED GLOMERULAR FILTRATION RATE IN EGYPTIAN CHRONIC HEPATITIS C PATIENTS". EKB Journal Management System, 42, 2, 2021, 7-13. doi: 10.21608/jmalexu.2021.244166
Ibrahim, E., Elbealy, M., Nassar, A., Mostafa, H. (2021). 'STUDY OF THE EFFECT OF SOFOSBUVIR BASED THERAPY ON ESTIMATED GLOMERULAR FILTRATION RATE IN EGYPTIAN CHRONIC HEPATITIS C PATIENTS', EKB Journal Management System, 42(2), pp. 7-13. doi: 10.21608/jmalexu.2021.244166
Ibrahim, E., Elbealy, M., Nassar, A., Mostafa, H. STUDY OF THE EFFECT OF SOFOSBUVIR BASED THERAPY ON ESTIMATED GLOMERULAR FILTRATION RATE IN EGYPTIAN CHRONIC HEPATITIS C PATIENTS. EKB Journal Management System, 2021; 42(2): 7-13. doi: 10.21608/jmalexu.2021.244166

STUDY OF THE EFFECT OF SOFOSBUVIR BASED THERAPY ON ESTIMATED GLOMERULAR FILTRATION RATE IN EGYPTIAN CHRONIC HEPATITIS C PATIENTS

Journal of the Medical Research Institute
Article 2, Volume 42, Issue 2, December 2021, Page 7-13  XML PDF (398.86 K)
Document Type: Review Article
DOI: 10.21608/jmalexu.2021.244166
View on SCiNiTO View on SCiNiTO
Authors
Elsaied Ibrahim1; Mohamed Ahmed Elbealy2; Abeer Abdelhafeez Nassar3; Hanan Mostafa Mostafa* 2
1Department of Internal Medicine, Faculty of Medicine, Alexandria University, Egypt
2Department of Internal Medicine, Medical Research Institute, Alexandria University, Egypt
3MBBCh, Faculty of Medicine, Alexandria University, Egypt
Abstract
Introduction: Recent Hepatitis C virus (HCV) treatments, direct-acting antiviral agents (DAAS), have shown >90% efficacy in hepatitis C virus treatment and achieving the goal of a sustained virological response (SVR).Sofosbuvir acts as an inhibitor of viral RNA synthesis through suppression of "NS5B protein of the virus. Thus, it appears to have a high barrier to develop resistance. Sofosbuvir is only administered orally and mainly excreted renally. The aim of the work was to study the effect of sofosbuvir based therapy on the estimated glomerular filtration rate (eGFR) of Egyptian chronic hepatitis C patients with normal kidney function or mild renal dysfunction. Subjects and methods: This study was carried out on 100 chronic hepatitis C patients with eGFR ≥ 60 ml/ min/1.73 m2 .Before starting treatment with DAAS, all patients were subjected to full history taking, clinical examination and laboratory investigations, including: HCV PCR, HBsAg, liver function tests, complete blood picture, prothrombin activity, alfa fetoprotein, fasting blood sugar,HBA1c and renal functions. eGFR was calculated by using the Chronic kidney disease- Epidemiology Collaboration equation (CKD-ECI).All tests were repeated at the end of treatment. Also abdominal ultrasound was performed before and after treatment. Results: There were no statistically significant differences in either renal function tests or eGFR before and after treatment. There were improvements in the liver enzymes, liver functions tests and Alfa fetoprotein. Conclusions: Sofosbuvir based therapy is safe and effective in treating chronic hepatitis C patients even in patients with mild chronic kidney diseases (CKD).
Keywords
Keywords: DAAS; CHC; eGFR; CKD. Abbreviations: (DAAs) Direct-acting antiviral agents; (CHC) Chronic hepatitis C; (eGFR) estimated glomerular filtration rate; (HCV) Hepatitis C virus; (CKD) Chronic kidney diseases; (NS5B) Non-structure protein 5B
Statistics
Article View: 126
PDF Download: 206